MMedXYNews
Ask AIHomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY News/Hematology-Oncology

Section

Hematology-Oncology

591 articles

Ask AI
All specialtiesHematology-OncologynewsClinical UpdatesCardiologyOncology

Latest updates

Allergy & Immunology

Secondary Autoimmune and Inflammatory Diseases Post-Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Clinical Outcomes from the EBMT Registry

This retrospective EBMT study identifies secondary autoimmune and inflammatory diseases as rare but significant complications following allo-HSCT, highlighting their incidence, risk factors, and impact on patient survival, calling for impro

Aug 2, 2026
Hematology-Oncology

Cytogenetic Insights into Multiple Myeloma Outcomes Despite MRD Negativity Post-Autologous Stem Cell Transplant

This study reveals that certain high-risk cytogenetic abnormalities continue to influence progression-free survival in multiple myeloma patients even after achieving deep MRD negativity post-ASCT, highlighting the need for tailored post-tra

Aug 2, 2026
Hematology-Oncology

EASIX and sC5b-9 Levels Predict TA-TMA Risk After Allo-HCT in Adults

A prospective study finds that baseline EASIX and day 14 sC5b-9 are independently associated with TA-TMA after allo-HCT, with combined stratification identifying high-risk adults.

Jul 27, 2026
Hematology-Oncology

Five-year OPTIC follow-up confirms benefit of response-based ponatinib dosing in chronic-phase CML

Five-year results from the OPTIC trial show that starting ponatinib at 45 mg then reducing to 15 mg upon response provides the best long-term efficacy and manageable safety in resistant CP-CML, particularly for T315I patients.

Jul 27, 2026
Hematology-Oncology

Extended HLA Haplotypes Linked to Survival After Hematopoietic Cell Transplantation

A study of 2,577 haploidentical transplants shows that extended HLA haplotypes, including a class III SNP, significantly influence mortality and relapse, potentially improving donor selection.

Jul 27, 2026
Hematology-Oncology

Ultralow-Dose IL-10–Expressing CAR T Cells Show Promising Activity in Relapsed/Refractory DLBCL

A phase 1 trial of ultralow-dose IL-10–expressing CD19 CAR T cells in 13 patients with R/R DLBCL reported a 92.3% objective response rate with manageable safety.

Jul 24, 2026
Clinical Updates

G3BP2-Mediated Venetoclax Resistance via ELF1-Driven MCL1 Transcription in Acute Myeloid Leukemia: Mechanisms and Therapeutic Implications

This review synthesizes evidence on the role of RNA-binding protein G3BP2 in conferring venetoclax resistance in AML through stabilizing ELF1 mRNA and upregulating MCL1 transcription, highlighting novel therapeutic avenues combining G3BP2 i

Jul 24, 2026Sign in to read
Hematology-Oncology

Measurable Residual Disease as a Prognostic Biomarker in Frontline Azacitidine and Venetoclax-Treated AML: Insights from the French VENAURA Registry

In AML patients receiving frontline azacitidine and venetoclax, achieving measurable residual disease negativity strongly predicts longer survival and lower relapse rates, overriding baseline risk factors, as shown in the French VENAURA reg

Jul 20, 2026
Hematology-Oncology

Blinatumomab Consolidation in High-Risk Ph-Negative B-Cell Acute Lymphoblastic Leukemia: Insights from the GRAALL-2014/B-QUEST Study

The GRAALL-2014/B-QUEST study demonstrates that integrating blinatumomab into consolidation and maintenance therapy significantly improves outcomes for adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukem

Jul 20, 2026Sign in to read
Hematology-Oncology

EIF4A3-Driven Nonsense-Mediated Decay: A Novel Regulatory Axis Modulating AML1-ETO9a Dosage and Clinical Outcomes in t(8;21) Acute Myeloid Leukemia

This review highlights how EIF4A3-dependent nonsense-mediated mRNA decay selectively regulates the oncogenic AML1-ETO9a isoform in t(8;21) AML, influencing leukemic cell proliferation, chemosensitivity, and patient survival through an isofo

Jul 17, 2026
Hematology-Oncology

Unraveling MDM4 Haploinsufficiency: A Novel TP53-Dependent Mechanism Driving Bone Marrow Failure Syndromes

MDM4 haploinsufficiency activates p53, causing diverse bone marrow failure phenotypes and hypocellular MDS, highlighting the pivotal MDM4-p53 axis in hematopoietic regulation and potential targets for intervention.

Jul 17, 2026Sign in to read
Hematology-Oncology

Navigating Dual Resistance in Extranodal NK/T-Cell Lymphoma: Challenges and Emerging Insights

Dual resistance to asparaginase and PD-1 inhibitors in extranodal NK/T-cell lymphoma leads to poor prognosis; chidamide-containing regimens show promising survival benefits in this difficult-to-treat population.

Jul 15, 2026
Cardiology

Molecular Mutations and Cardiovascular Risks Shape Prognosis in Triple-Negative Essential Thrombocythemia

This study reveals that specific gene mutations and cardiovascular risk factors significantly influence prognosis and thrombotic risk in triple-negative essential thrombocythemia, highlighting the importance of molecular profiling for perso

Jul 15, 2026
Hematology-Oncology

Noncanonical FLT3-ITD Signaling Drives Immune Evasion via PKCι-STAT1–Mediated CD8+ T-Cell Exhaustion in Acute Myeloid Leukemia

FLT3-ITD mutations in AML promote immune evasion through a novel PKCι–STAT1 signaling axis that induces CD276-mediated CD8+ T-cell exhaustion, offering a promising target for combined FLT3 and CD276-directed therapies.

Jul 15, 2026Sign in to read
Hematology-Oncology

Early Software-Assisted Evaluation Enhances Prediction of Survival in Newly Diagnosed Chronic Graft-versus-Host Disease Patients

Software-assisted response evaluation at six months reliably predicts survival outcomes in chronic graft-versus-host disease, offering a promising tool to guide treatment decisions and improve patient prognosis.

Jul 13, 2026
Hematology-Oncology

Pavurutamab, a BCMA-Targeting Bispecific T-Cell Engager: Promising Phase 1/1b Results in Triple-Class Relapsed/Refractory Multiple Myeloma

Pavurutamab demonstrates manageable safety and encouraging efficacy in heavily pretreated relapsed/refractory multiple myeloma, showing an overall response rate of 46.5% and median progression-free survival of 16.8 months at the recommended

Jul 13, 2026
Hematology-Oncology

Fludarabine with Treosulfan vs. Total Body Irradiation as Conditioning in ALL Transplantation: A Comparative Retrospective Analysis

This retrospective matched-pair study compares fludarabine combined with treosulfan or total body irradiation as conditioning regimens before allogeneic stem cell transplantation in adult acute lymphoblastic leukemia, finding no significant

Jul 12, 2026Sign in to read
Hematology-Oncology

Unraveling Genetic Drivers in Triple Negative Thrombocytosis: Implications of MPL and SH2B3/LNK Mutations

Comprehensive genetic screening of triple negative thrombocytosis reveals germline MPL compound mutations and truncating SH2B3/LNK alterations, offering new insights into diagnosis and personalized management.

Jul 12, 2026Sign in to read
Superintelligence

MAIPI: A Novel AI-Powered Prognostic Index for Mantle Cell Lymphoma Using Routine Histology

The MAIPI deep learning model offers a novel, accurate prognosis tool for mantle cell lymphoma, using standard H&E stained biopsy images, bypassing need for molecular tests or expert pathology, and enhancing risk stratification for indi

Jul 12, 2026Sign in to read
Hematology-Oncology

Decoding PIEZO1 Variants: Precision Insights into Hereditary Red Blood Cell and Iron Disorders

This study refines the classification of PIEZO1 variants using integrative genomic and phenotypic data, enhancing diagnosis and personalized management of hereditary red blood cell and iron disorders like dehydrated hereditary stomatocytosi

Jul 12, 2026
Previous
13 / 25
1…1112131415…25
Next

Most read

  1. 01Hematology-Oncology

    Precision Immunotherapy in Acute Myeloid Leukemia: Advancing Beyond Traditional Targets

  2. 02Hematology-Oncology

    Targeting MERTK in CLL: A Promising Strategy for Overcoming Ibrutinib Resistance

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.